Real-world experience from the TRIO network assessing outcomes in patients with chronic hepatitis C treated with elbasvir/grazoprevir in the United States
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2018
Price : $35 *
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- 05 Jun 2018 Updated results (n=319) of retrospective data analyses assessing utilization and outcomes with elbasvir/grazoprevir (EBR/GZR)-containing regimens in an updated cohort of genotype 1B chronic hepatitis C patients treated as part of the TRIO network in the US, presented at the Digestive Disease Week 2018.
- 05 Jun 2018 Updated results (n=115) presented at the Digestive Disease Week 2018.
- 17 Apr 2018 Results (n=470) assessing uptake, healthcare utilization and outcomes of chronic hepatitis C treated with elbasvir/grazoprevirin the United States, were published in the Alimentary Pharmacology and Therapeutics.